• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小纤维受累与晚发性庞贝病的临床疼痛无关。

Small fiber involvement is independent from clinical pain in late-onset Pompe disease.

机构信息

Department of Neurology, BG University Hospital Bergmannsheil, Ruhr-University, Bochum, Germany.

Heimer-Institute for Muscle Research, BG University Hospital Bergmannsheil, Ruhr-University, Bochum, Germany.

出版信息

Orphanet J Rare Dis. 2022 Apr 27;17(1):177. doi: 10.1186/s13023-022-02327-4.

DOI:10.1186/s13023-022-02327-4
PMID:35477515
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9044713/
Abstract

BACKGROUND

Pain occurs in the majority of patients with late onset Pompe disease (LOPD) and is associated with a reduced quality of life. The aim of this study was to analyse the pain characteristics and its relation to a small nerve fiber involvement in LOPD patients.

METHODS

In 35 patients with LOPD under enzyme replacement therapy without clinical signs of polyneuropathy (19 females; 51 ± 15 years), pain characteristics as well as depressive and anxiety symptoms were assessed using the PainDetect questionnaire (PDQ) and the hospital anxiety and depression scale (HADS), respectively. Distal skin biopsies were analysed for intraepidermal nerve fiber density (IENFD) and compared to age- and gender-matched reference data. Skin biopsies from 20 healthy subjects served as controls to assure validity of the morphometric analysis.

RESULTS

Pain was reported in 69% of the patients with an average intensity of 4.1 ± 1.1 on the numeric rating scale (NRS; anchors: 0-10). According to PDQ, neuropathic pain was likely in one patient, possible in 29%, and unlikely in 67%. Relevant depression and anxiety symptoms occurred in 31% and 23%, respectively, and correlated with pain intensity. Distal IENFD (3.98 ± 1.95 fibers/mm) was reduced in 57% of the patients. The degree of IENFD reduction did not correlate with the durations of symptoms to ERT or duration of ERT to biopsy.

CONCLUSIONS

Pain is a frequent symptom in treated LOPD on ERT, though a screening questionnaire seldom indicated neuropathic pain. The high frequency of small nerve fiber pathology in a treated LOPD cohort was found regardless of the presence of pain or comorbid risk factors for SFN and needs further exploration in terms of clinical context, exact mechanisms and when developing novel therapeutic options for LOPD.

摘要

背景

大多数迟发性庞贝病(LOPD)患者都会出现疼痛,且生活质量降低。本研究旨在分析 LOPD 患者的疼痛特征及其与小纤维神经受累的关系。

方法

在 35 名接受酶替代治疗且无周围神经病变临床症状的 LOPD 患者(19 名女性;51±15 岁)中,采用疼痛检测问卷(PDQ)和医院焦虑抑郁量表(HADS)分别评估疼痛特征、抑郁和焦虑症状。分析远端皮肤活检的表皮内神经纤维密度(IENFD),并与年龄和性别匹配的参考数据进行比较。20 名健康受试者的皮肤活检作为对照,以确保形态计量分析的有效性。

结果

69%的患者报告有疼痛,平均数字评定量表(NRS)评分 4.1±1.1(锚定:0-10)。根据 PDQ,1 例患者可能为神经病理性疼痛,29%可能为神经病理性疼痛,67%不太可能为神经病理性疼痛。分别有 31%和 23%的患者出现相关抑郁和焦虑症状,且与疼痛强度相关。57%的患者远端 IENFD(3.98±1.95 纤维/mm)减少。IENFD 减少的程度与 ERT 症状持续时间或 ERT 到活检的持续时间无关。

结论

尽管筛查问卷很少提示神经病理性疼痛,但在接受 ERT 的治疗性 LOPD 中,疼痛是一种常见症状。在一个接受治疗的 LOPD 队列中,无论是否存在疼痛或 SFN 的合并风险因素,都发现小纤维神经病变的发生率很高,需要进一步从临床背景、确切机制以及为 LOPD 开发新的治疗方法等方面进行探讨。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1203/9044713/52139d3a0293/13023_2022_2327_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1203/9044713/2f49f3c46fcb/13023_2022_2327_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1203/9044713/355e07f35c8a/13023_2022_2327_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1203/9044713/3d49fa6a583b/13023_2022_2327_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1203/9044713/9e6bc0d28760/13023_2022_2327_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1203/9044713/52139d3a0293/13023_2022_2327_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1203/9044713/2f49f3c46fcb/13023_2022_2327_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1203/9044713/355e07f35c8a/13023_2022_2327_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1203/9044713/3d49fa6a583b/13023_2022_2327_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1203/9044713/9e6bc0d28760/13023_2022_2327_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1203/9044713/52139d3a0293/13023_2022_2327_Fig5_HTML.jpg

相似文献

1
Small fiber involvement is independent from clinical pain in late-onset Pompe disease.小纤维受累与晚发性庞贝病的临床疼痛无关。
Orphanet J Rare Dis. 2022 Apr 27;17(1):177. doi: 10.1186/s13023-022-02327-4.
2
White matter lesions in treated late onset Pompe disease are not different to matched controls.治疗后的晚发性庞贝病的白质病变与匹配对照组无差异。
Mol Genet Metab. 2019 Jun;127(2):128-131. doi: 10.1016/j.ymgme.2019.05.007. Epub 2019 May 14.
3
Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).短时间到长时间酶替代疗法(ERT)对晚发性庞贝病(LOPD)骨骼肌组织的影响。
Neuropathol Appl Neurobiol. 2018 Aug;44(5):449-462. doi: 10.1111/nan.12414. Epub 2017 Jul 4.
4
Association between under-dose of enzyme replacement therapy and quality of life in adults with late-onset Pompe disease in China: A retrospective matched cohort study.中国晚发性庞贝病成人酶替代治疗剂量不足与生活质量的关系:一项回顾性匹配队列研究。
PLoS One. 2024 Sep 17;19(9):e0310534. doi: 10.1371/journal.pone.0310534. eCollection 2024.
5
36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry.36 个月随访评估:晚发性庞贝病停止和重新开始酶替代治疗后的结果:来自瑞士庞贝病登记处的数据。
J Neurol. 2018 Dec;265(12):2783-2788. doi: 10.1007/s00415-018-9065-7. Epub 2018 Sep 19.
6
The emerging phenotype of late-onset Pompe disease: A systematic literature review.晚发型庞贝病的新出现表型:一项系统文献综述。
Mol Genet Metab. 2017 Mar;120(3):163-172. doi: 10.1016/j.ymgme.2016.12.004. Epub 2016 Dec 11.
7
Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.比利时的晚发性庞贝病(LOPD):临床特征和疗效评估。
Orphanet J Rare Dis. 2020 Apr 5;15(1):83. doi: 10.1186/s13023-020-01353-4.
8
Small fiber neuropathy is a common feature of Ehlers-Danlos syndromes.小纤维神经病变是埃勒斯-当洛综合征的常见特征。
Neurology. 2016 Jul 12;87(2):155-9. doi: 10.1212/WNL.0000000000002847. Epub 2016 Jun 15.
9
The humanistic burden of Pompe disease: are there still unmet needs? A systematic review.庞贝病的人文负担:仍有未满足的需求吗?一项系统综述。
BMC Neurol. 2017 Nov 22;17(1):202. doi: 10.1186/s12883-017-0983-2.
10
Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group.评估抗 rh-GAA 在意大利 GSDII 研究组晚发性庞贝病队列中的 ERT 反应调节作用。
Adv Ther. 2019 May;36(5):1177-1189. doi: 10.1007/s12325-019-00926-5. Epub 2019 Mar 16.

引用本文的文献

1
Sensory neuropathy in patients with Pompe disease: a case series in Iran.庞贝病患者的感觉神经病变:伊朗的病例系列研究
BMC Musculoskelet Disord. 2024 Dec 27;25(1):1078. doi: 10.1186/s12891-024-08220-4.
2
Characterization of the neuropathic pain component contributing to myalgia in patients with myotonic dystrophy type 1 and 2.1型和2型强直性肌营养不良患者中导致肌痛的神经性疼痛成分的特征分析
Front Neurol. 2024 Aug 13;15:1414140. doi: 10.3389/fneur.2024.1414140. eCollection 2024.
3
Nociceptive Pain in Patients with Neuromuscular Disorders: A Cross-Sectional Clinical Study.

本文引用的文献

1
Diagnosing small fiber neuropathy in clinical practice: a deep phenotyping study.临床实践中诊断小纤维神经病变:一项深度表型研究。
Ther Adv Neurol Disord. 2021 Mar 23;14:17562864211004318. doi: 10.1177/17562864211004318. eCollection 2021.
2
Clinical diagnosis and management of small fiber neuropathy: an update on best practice.临床小纤维神经病的诊断和管理:最佳实践更新。
Expert Rev Neurother. 2020 Sep;20(9):967-980. doi: 10.1080/14737175.2020.1794825. Epub 2020 Jul 23.
3
Diagnostic utility of small fiber analysis in skin biopsies from children with chronic pain.
神经肌肉疾病患者的伤害感受性疼痛:一项横断面临床研究。
J Neuromuscul Dis. 2024;11(5):1111-1122. doi: 10.3233/JND-240068.
4
[Research progress of nervous system damage in Pompe disease].庞贝病神经系统损害的研究进展
Zhongguo Dang Dai Er Ke Za Zhi. 2023 Apr 15;25(4):420-424. doi: 10.7499/j.issn.1008-8830.2211052.
皮肤活检中小纤维分析对儿童慢性疼痛的诊断价值。
Muscle Nerve. 2020 Feb;61(2):173-181. doi: 10.1002/mus.26766. Epub 2019 Dec 9.
4
Late-onset Pompe disease associated with polyneuropathy.迟发性庞贝病合并多发性神经病。
Neuromuscul Disord. 2019 Dec;29(12):968-972. doi: 10.1016/j.nmd.2019.08.016. Epub 2019 Sep 13.
5
Diagnostic criteria for small fibre neuropathy in clinical practice and research.临床实践和研究中小纤维神经病的诊断标准。
Brain. 2019 Dec 1;142(12):3728-3736. doi: 10.1093/brain/awz333.
6
An integrative correlation of myopathology, phenotype and genotype in late onset Pompe disease.迟发性庞贝病的肌病学、表型和基因型的综合相关性。
Neuropathol Appl Neurobiol. 2020 Jun;46(4):359-374. doi: 10.1111/nan.12580. Epub 2019 Oct 24.
7
Multisystem late onset Pompe disease (LOPD): an update on clinical aspects.多系统晚发型庞贝病(LOPD):临床方面的最新进展
Ann Transl Med. 2019 Jul;7(13):284. doi: 10.21037/atm.2019.07.24.
8
Long-term outcome and unmet needs in infantile-onset Pompe disease.婴儿型庞贝病的长期预后及未满足的需求
Ann Transl Med. 2019 Jul;7(13):283. doi: 10.21037/atm.2019.04.70.
9
Mobility assessment using wearable technology in patients with late-onset Pompe disease.在晚发型庞贝病患者中使用可穿戴技术进行运动能力评估。
NPJ Digit Med. 2019 Jul 22;2:70. doi: 10.1038/s41746-019-0143-8. eCollection 2019.
10
Severe distal muscle involvement and mild sensory neuropathy in a boy with infantile onset Pompe disease treated with enzyme replacement therapy for 6 years.经酶替代治疗 6 年的婴儿起病 Pompe 病患儿出现严重的远端肌肉受累和轻度感觉性周围神经病。
Neuromuscul Disord. 2019 Jun;29(6):477-482. doi: 10.1016/j.nmd.2019.03.004. Epub 2019 Mar 14.